A 58-year-old woman without clinical cardiovascular disease, non-smoker, with LDL-C 3.6 mmol/L and 10-year Framingham risk of 18% attends your family ...

Question

A 58-year-old woman without clinical cardiovascular disease, non-smoker, with LDL-C 3.6 mmol/L and 10-year Framingham risk of 18% attends your family practice. According to the 2021 Canadian Cardiovascular Society dyslipidaemia guideline, which lipid-lowering approach is most appropriate?

Accepted Answer

Initiate moderate- to high-intensity statin aiming for LDL-C  =50% reduction

Answer

Reassure, no statin indicated at this risk level

Answer

Initiate low-dose statin aiming for any LDL reduction

Answer

Use ezetimibe monotherapy

Answer

Use PCSK9 inhibitor monotherapy

ca-mccqe1 MCQ (SBA): Primary prevention dyslipidaemia

A 58-year-old woman without clinical cardiovascular disease, non-smoker, with LDL-C 3.6 mmol/L and 10-year Framingham risk of 18% attends your family practice. According to the 2021 Canadian Cardiovascular Society dyslipidaemia guideline, which lipid-lowering approach is most appropriate?